WCLC 2025 - Posters & ePosters-EP.13.15 Outcome and Safety of Lurbinectedin as Compassionate Use in SCLC: A Retrospective Multicentric International Study

EP.13.15 Outcome and Safety of Lurbinectedin as Compassionate Use in SCLC: A Retrospective Multicentric International Study

Back to course

Pdf Summary

This retrospective multicentric international study evaluated the effectiveness and safety of lurbinectedin, used under compassionate use conditions, in patients with extensive-stage small cell lung cancer (ES-SCLC) treated in second or later lines. The study involved cohorts from the Netherlands and Italy, with a focus on real-world outcomes within a named patient program.<br /><br />Key findings include an overall response rate (ORR) of 23.1% and a disease control rate (DCR) of 45.4% across the combined population, with the Dutch cohort showing slightly higher ORR (24.5%) and DCR (48.0%) compared to the Italian cohort (ORR 14.7%, DCR 29.4%). The median duration of response (mDOR) was approximately 2.8 months overall, longer in the Italian cohort at 4.6 months. The 6-month progression-free survival (PFS) rate was 12.2%, and the overall 6-month overall survival (OS) rate was 42.4%. Outcomes were negatively influenced by poorer performance status (PS 2) at lurbinectedin initiation, shorter chemotherapy-free interval (CFI ≤90 days), and the presence of brain or liver metastases.<br /><br />Safety assessments suggest that lurbinectedin is generally well tolerated. The study highlights the potential benefit of using central venous catheters (CVC) to reduce thromboembolic events and phlebitis. It also suggests careful evaluation of the role of primary prophylactic granulocyte colony-stimulating factor (G-CSF) administration.<br /><br />In conclusion, compassionate use of lurbinectedin in advanced lines demonstrates efficacy and manageable safety for ES-SCLC patients. Specific clinical factors such as performance status and metastatic burden influence outcomes. The study supports considering lurbinectedin as a valuable treatment option in real-world ES-SCLC management, with attention to supportive care measures to optimize patient safety.

Asset Subtitle

Daniela Scattolin

Meta Tag

Speaker Daniela Scattolin

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

lurbinectedin

extensive-stage small cell lung cancer

ES-SCLC

compassionate use

overall response rate

disease control rate

progression-free survival

overall survival

performance status

thromboembolic events